DocSym
β
Searchsearch
Search
(B20.6) Hiv disease resulting in pneumocystis jirovecii pneumonia
More details coming soon
192 874 in individuals diagnosis hiv disease resulting in pneumocystis jirovecii pneumonia confirmed
53 831 deaths with diagnosis hiv disease resulting in pneumocystis jirovecii pneumonia
28% mortality rate associated with the disease hiv disease resulting in pneumocystis jirovecii pneumonia
Diagnosis hiv disease resulting in pneumocystis jirovecii pneumonia is diagnosed Men are 50.54% more likely than Women
145 181
Men receive the diagnosis hiv disease resulting in pneumocystis jirovecii pneumonia
38 026 (26.2 %)Died from this diagnosis.
100
95
90
85
80
75
70
65
60
55
50
45
40
35
30
25
20
15
10
5
0
47 693
Women receive the diagnosis hiv disease resulting in pneumocystis jirovecii pneumonia
15 805 (33.1 %)Died from this diagnosis.
Risk Group for the Disease hiv disease resulting in pneumocystis jirovecii pneumonia - Men and Women aged 35-39
In Men diagnosis is most often set at age 0-9, 20-79
Less common in men the disease occurs at Age 10-19, 80-95+Less common in women the disease occurs at Age 0-5, 10-14, 70-74, 90-95+
In Women diagnosis is most often set at age 5-9, 15-69, 75-89
Disease Features hiv disease resulting in pneumocystis jirovecii pneumonia
Absence or low individual and public risk
Hiv disease resulting in pneumocystis jirovecii pneumonia - what does this mean
More details coming soon
What happens during the disease - hiv disease resulting in pneumocystis jirovecii pneumonia
The hiv virus weakens the immune system, allowing for pneumocystis jirovecii pneumonia to take hold in the lungs. the virus increases the risk of infection from the fungus by preventing the body from being able to fight off the infection. this leads to an increased production of mucus, which can cause difficulty in breathing, and can eventually lead to respiratory failure.
Clinical Pattern
More details coming soon
How does a doctor diagnose
- Complete physical examination
- Laboratory tests to detect HIV infection
- Chest X-ray to detect Pneumocystis jirovecii pneumonia
- Sputum testing to detect Pneumocystis jirovecii pneumonia
- CT scan of the chest to detect Pneumocystis jirovecii pneumonia
- Bronchoscopy to detect Pneumocystis jirovecii pneumonia
- Lung biopsy to detect Pneumocystis jirovecii pneumonia
Treatment and Medical Assistance
Main goal of the treatment: To reduce the risk of progression of HIV disease resulting in Pneumocystis jirovecii pneumonia.
- Administer antiretroviral therapy (ART) to suppress viral replication
- Provide prophylactic antibiotics to prevent secondary bacterial infection
- Administer corticosteroids to reduce inflammation
- Provide supplemental oxygen to improve oxygenation
- Administer bronchodilators to reduce airway obstruction
- Administer immunomodulators to boost the immune system
- Provide nutritional support to improve nutrition status
- Provide respiratory support to improve ventilation and oxygenation
- Provide physical and occupational therapy to improve mobility
- Provide psychological support to reduce anxiety and depression
33 Days of Hospitalization Required
Average Time for Outpatient Care Not Established
Hiv disease resulting in pneumocystis jirovecii pneumonia - Prevention
The best way to prevent hiv disease resulting in pneumocystis jirovecii pneumonia is to practice safe sex, get tested regularly, and get vaccinated against other infections that can increase the risk of acquiring hiv. additionally, it is important to avoid sharing needles and other drug paraphernalia.